TITLE:
Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis

CONDITION:
Candidiasis

INTERVENTION:
FK463

SUMMARY:

      The purpose of the study is to evaluate the safety and efficacy of FK463 in the treatment of
      patients with confirmed candidemia or invasive candidiasis.
    

DETAILED DESCRIPTION:

      This will be an open-label, non-comparative study of intravenous FK463. Enrollment will
      include at least 100 patients evaluable for efficacy.
    

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

          -  Has Candidemia or invasive candidiasis documented by typical clinical signs and
             symptoms and confirmed by fungal culture or histologic confirmation

        Exclusion Criteria

          -  Has abnormal liver test parameters, e.g., AST or ALT > 10 times upper limit of normal

          -  Has life expectancy judged to be less than 5 days

          -  De novo patients who have received a systemic antifungal agent for the treatment of
             this episode of candidemia or invasive candidiasis for more than 48 hours prior to
             the first dose of FK463; or efficacy failure patients who have received =< 5 days of
             prior systemic antifungal therapy for the treatment of this episode of candidemia or
             invasive candidiasis

          -  Require treatment with topical or systemic antifungal agents for conditions other
             than candidemia or invasive candidiasis
      
